GTHP (Guided Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GTHP Guided Therapeutics Inc GTHP
19 GF Score
Price $0.25
GF Value $1.08
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Guided Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Guided Therapeutics  (OTCPK:GTHP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Guided Therapeutics Cyclically Adjusted PB Ratio Related Terms


Guided Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics Cyclically Adjusted PB Ratio Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Guided Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GTHP vs PETV, FOFA, CTSO: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Guided Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Cyclically Adjusted PB Ratio falls into.


GTHP
19GF Score
Guided Therapeutics Inc GTHP
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guided Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Guided Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Guided Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.067/333.9520*333.9520
=-0.067

Current CPI (Jun. 2026) = 333.9520.

Guided Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 241.428 0.000
201612 -10,568.000 241.432 -14,617.800
201703 -5,133.500 243.801 -7,031.729
201706 -3,836.333 244.955 -5,230.149
201709 -1,123.083 246.819 -1,519.558
201712 -329.968 246.524 -446.989
201803 -109.191 249.554 -146.119
201806 -44.893 251.989 -59.495
201809 -31.200 252.439 -41.275
201812 -6.231 251.233 -8.283
201903 -5.066 254.202 -6.655
201906 -5.842 256.143 -7.617
201909 -5.672 256.759 -7.377
201912 -5.345 256.974 -6.946
202003 -1.056 258.115 -1.366
202006 -1.438 257.797 -1.863
202009 -1.255 260.280 -1.610
202012 -1.033 260.474 -1.324
202103 -0.893 264.877 -1.126
202106 -0.918 271.696 -1.128
202109 -0.879 274.310 -1.070
202112 -0.901 278.802 -1.079
202203 -0.498 287.504 -0.578
202206 -0.399 296.311 -0.450
202209 -0.134 296.808 -0.151
202212 -0.123 296.797 -0.138
202303 -0.116 301.836 -0.128
202306 -0.124 305.109 -0.136
202309 -0.128 307.789 -0.139
202312 -0.126 306.746 -0.137
202403 -0.126 312.332 -0.135
202406 -0.137 314.175 -0.146
202409 -0.131 315.301 -0.139
202412 -0.121 315.605 -0.128
202503 -0.093 319.799 -0.097
202506 -0.097 322.561 -0.100
202509 -0.087 324.800 -0.089
202512 -0.088 324.054 -0.091
202603 -0.061 330.213 -0.062
202606 -0.067 333.952 -0.067

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Guided Therapeutics (GTHP) Overvalued in 2026?

Based on GuruFocus' analysis, Guided Therapeutics stock appears to be undervalued. The current stock price of $0.25 is trading 76.9% below its estimated GF Value™ of $1.08. GuruFocus considers Guided Therapeutics to be Possible Value Trap.

Key valuation signals for GTHP:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $1.08 vs. price of $0.25 (76.9% below fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the GTHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
19GF Score

Get the complete analysis for GTHP

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$1.08
GF Value